Source comparison
Men 45-55 Andropause MK-677 Protocol: Dosing Comparison
10mg 30–50% 20–35% Introductory phase, appetite-sensitive individuals Minimal water retention, mild appetite increase Suboptimal for full andropause symptom reversal. Consider as initial titration only 15mg 50–70% 35–50% Maintenance dosing, long-term use Moder
This comparison does not assign a generated winner or score.
- 10mg
- 30–50%
- 20–35%
- Introductory phase, appetite-sensitive individuals
- Minimal water retention, mild appetite increase
- Suboptimal for full andropause symptom reversal. Consider as initial titration only
- 15mg
- 50–70%
- 35–50%
- Maintenance dosing, long-term use
- Moderate appetite increase, occasional transient edema
- Effective middle ground for sustained use with lower side effect burden
- 25mg
- 60–90%
- 40–80%
- Standard clinical dose, body recomposition focus
- Notable appetite increase in 60% of users, water retention in 20–30%
- Gold standard dose backed by long-term safety data. Best balance of efficacy and tolerability
- 30–50mg
- Minimal additional benefit beyond 25mg
- Minimal additional benefit
- Not recommended
- Increased fasting glucose, higher water retention risk
- Offers no meaningful advantage over 25mg. Higher doses compound side effects without proportional benefit